PET/CT Characterization of Treatment Resistance
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This study will use different types of medical imaging to assess how lesions from advanced prostate cancer become resistant to second-generation AR-targeted therapy, and how the different types of imaging compare in that assessment. Participants in this study have advanced prostate cancer and are either scheduled to start a second-generation androgen receptor (AR) targeted therapy (such as enzalutamide, abiraterone, or apalutamide) or are already being treated with one. Participants can expect to be in the study for at least 9 months, and up to 2 years.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Potwierdzony histologicznie rak prostaty
- •Przerzuty widoczne w badaniach obrazowych (CT lub skan kości)
- •Progresja raka prostaty potwierdzona wzrostem poziomu PSA
- •Kwalifikacja do leczenia nowymi inhibitorami receptora androgenowego lub terapią radioligandową
- •Wiek powyżej 18 lat
- •Możliwość pozostania nieruchomym przez co najmniej 30 minut podczas badania
- •Oczekiwana długość życia co najmniej 12 miesięcy
✗ Disqualifies
- •Niekontrolowana cukrzyca
- •Wcześniejsze leczenie nowymi inhibitorami receptora androgenowego w zaawansowanym stadium choroby
- •Ból lub objawy wymagające silnych leków przeciwbólowych
- •Rak prostaty typu neuro-endokrynnego
- •Wcześniejsza terapia radioaktywna raka prostaty opornego na kastrację
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- October 1, 2026
- Sex
- Male only
Therapies / drugs in trial
Locations (1)
University of Wisconsin
Madison, United States
Trial contact
Cancer Connect
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 9/2/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.